ReviewMicroorganisms2024
Bacterial Contamination of Platelet Products.
Review in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Assessment of the efficacy of large volume delayed sampling primary culture and pathogen reduction in preventing septic reactions from platelet transfusions.Transfusion · 2026Review
- Bacterial screening of platelet donations in England, 2014-2023.Vox sanguinis · 2026Article
- Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017-2024.Vox sanguinis · 2026Article
- Effects of platelet-rich plasma on cutaneous flap healing in rabbits: a pilot comparative experimental study with adipose tissue.Scientific reports · 2026Article
- Pathogen Reduction of Transfused Blood Components-The End of the Beginning Rather than the Beginning of the End.Pathogens (Basel, Switzerland) · 2026Review
- Monitoring bacterial contamination of blood components at the Croatian Institute of Transfusion Medicine-Evolution of strategies and results in a 14-year period (2011-2024).Vox sanguinis · 2026Article
- Practices in platelet production: A Nordic perspective (2018-2022).Vox sanguinis · 2026Article
- Article
- Bacterial Contamination in Stored Blood for Transfusion and Associated Infectious Risks Among Patients with Cancer at Mbarara Regional Referral Hospital, in Uganda.Journal of blood medicine · 2026Article
- Low bacterial contamination rate in platelet components following primary culture screening: a Saudi Arabian experience.Frontiers in medicine · 2026Article
- Heuristic platelet issuing policies for an integrated ABO blood bank system under heterogeneous demand: towards patient-centric management.Frontiers in health services · 2026Article
- Nylon Affinity Networks Capture and Sequester Two Model Bacteria Spiked in Human Plasma.Pathogens (Basel, Switzerland) · 2025Article
- Preliminary determination of bacterial contamination of whole blood units in a Ghanaian blood bank: Providing evidence to improve transfusion safety.Vox sanguinis · 2025Article
- Implementation of a blood proficiency testing scheme for bacterial screening of platelet components.Vox sanguinis · 2025Article
- Alterations in RNA Expression Profile FollowingInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transfusion of bacterially contaminated platelets, although rare, is still a major cause of mortality and morbidity despite the introduction of many methods to limit this over the past 20 years. The methods used include improved donor skin disinfection, diversion of the first part of donations, use of apheresis platelet units rather than whole-blood derived pools, primary and secondary testing by culture or rapid test, and use of pathogen reduction. Primary culture has been in use the US since 2004, using culture 24 h after collection of volumes of 4-8 mL from apheresis collections and whole-blood derived pools inoculated into aerobic culture bottles, with limited use of secondary testing by culture or rapid test to extend shelf-life from 5 to 7 days. Primary culture was introduced in the UK in 2011 using a "large-volume, delayed sampling" (LVDS) protocol requiring culture 36-48 h after collection of volumes of 16 mL from split apheresis units and whole-blood derived pools, inoculated into aerobic and anaerobic culture bottles (8 mL each), with a shelf-life of 7 days. Pathogen reduction using amotosalen has been in use in Europe since 2002, and was approved for use in the US in 2014. In the US, recent FDA guidance, effective October 2021, recommended several strategies to limit bacterial contamination of platelet products, including pathogen reduction, variants of the UK LVDS method and several two-step strategies, with shelf-life ranging from 3 to 7 days. The issues associated with bacterial contamination and these strategies are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.